This ambitious endeavor pooled patients from both SEER and the NCDB to update our understanding of the epidemiology, treatment patterns, and survival of metastatic disease at large. Indeed, there have been a lot of changes to observe over the studied time period from 1998-2015. Cancers with effective screening available have seen a decrease in incidence of metastatic disease (lung and colon) while those without saw an increase (pancreatic). The use of systemic—but not local—therapies has increased across almost all metastatic disease, particularly immunotherapy. The upshot is that patients diagnosed 2006-2010 had 17.4% higher odds of being alive at 5 years compared with those diagnosed 1998-2002. | Lehrer, Am J Clin Oncol 2021


Popular Posts